Related Experiment Videos

Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia

M Smeyne1, O Goloubeva, R J Smeyne

  • 1Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee 38015, USA.

Glia
|April 18, 2001
PubMed

Insights

Glial cells, not neurons, determine sensitivity to MPTP, a toxin causing Parkinsonism. This finding reveals glia as a key target for developing new Parkinson's disease therapies.

Area of Science:

  • Neuroscience
  • Toxicology
  • Genetics

Background:

  • Parkinson's disease (PD) affects 2% of individuals over 50.
  • PD is thought to result from genetic and environmental factors.
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces parkinsonism, but its strain-specific mechanism in mice is unclear.

Purpose of the Study:

  • To investigate the mechanism of MPTP strain specificity in experimental parkinsonism.
  • To identify the critical cell type responsible for MPTP sensitivity.

Main Methods:

  • Utilized novel chimeric murine substantia nigra cultures.
  • Co-cultured dopaminergic neurons and glia from MPTP-sensitive (C57Bl/6J) and resistant (SWR/J) mouse strains.
  • Assessed neuronal loss after exposure to MPP+, the toxic metabolite of MPTP.

Main Results:

  • MPTP sensitivity is conferred by glial cells, not dopaminergic neurons.
  • C57Bl/6J neurons showed significantly higher MPP+-induced loss when cultured on C57Bl/6J glia compared to SWR/J glia.
  • SWR/J neurons showed minimal loss on SWR/J glia but increased loss on C57Bl/6J glia.
  • The MAO-B conversion of MPTP to MPP+ was not involved in the observed strain specificity.

Conclusions:

  • Glial cells are the critical determinants of susceptibility to MPTP-induced neurotoxicity.
  • This discovery identifies glia as a potential therapeutic target for Parkinson's disease.
  • Understanding glial roles may lead to novel anti-parkinsonian treatments.

Related Concept Videos